Cargando…

Sword 1 and 2: Subgroup Analysis of 48 Week Results by Age, Race and Gender

BACKGROUND: Switching to the 2-drug regimen (2DR) of DTG+RPV was proven non-inferior to continuing a suppressive PI-, INI- or NNRTI- based current antiretroviral regimen (CAR) at Week 48. This analysis evaluated the efficacy and safety of switching from CAR to DTG+RPV by age, race and gender subgrou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Walmsley, Sharon, Richmond, Gary, Bredeek, Fritz, Ramgopal, Moti, Hung, Chien-Ching, Blair, Elizabeth, Kahl, Lesley, Underwood, Mark, Angelis, Kostas, Vandermeulen, Kati, Wynne, Brian, Aboud, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631252/ http://dx.doi.org/10.1093/ofid/ofx163.1078

Ejemplares similares

Brief Report: Evaluation of Inflammation and Atherogenesis Biomarkers Through 148 Weeks Postswitch to Dolutegravir and Rilpivirine in SWORD-1/SWORD-2
por: Llibre, Josep M., et al.
Publicado: (2022)

Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials
por: van Wyk, Jean, et al.
Publicado: (2020)

2484. Patient Reported Outcomes After Switching to a 2-Drug Regimen of Dolutegravir + Rilpivirine: Week 148 Results from the Sword-1 and Sword-2 Studies
por: Oglesby, Alan, et al.
Publicado: (2019)

319. SWORD 1 and 2: Switch from TDF Containing Regimen to DTG+RPV Maintains Bone Mineral Density and Decreases Bone Turnover Markers Over 148 Weeks
por: Kahl, Lesley, et al.
Publicado: (2019)

75. High Rates of Virologic Suppression with DTG/3TC in Newly Diagnosed Adults with HIV-1 Infection and Baseline Viral Load >500,000 c/mL: 48-Week Subgroup Analysis of the STAT Study
por: Rolle, Charlotte-Paige M, et al.
Publicado: (2021)

Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health
por: McComsey, Grace A., et al.
Publicado: (2018)

Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks
por: Rolle, Charlotte-Paige, et al.
Publicado: (2023)

Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials
por: Raffi, François, et al.
Publicado: (2015)

Evaluating Diversity in Randomized Clinical Trials of Dolutegravir-Based Antiretroviral Therapy Regimens: Pooled 48-Week Analyses by Race, Sex, and Regional Subgroups
por: Rawlings, M Keith, et al.
Publicado: (2022)

1046. Week 48 Outcomes from the BRAAVE 2020 Study: A Randomized Switch to B/F/TAF in African American Adults with HIV
por: Hagins, Debbie, et al.
Publicado: (2020)

887. High Rates of Virologic Suppression Achieved in HIV-1–Infected Adults Rapidly Starting Antiretroviral Therapy (ART) with the Single-Tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) 800/150/200/10 mg Regardless of Baseline Disease Characteristics: Week 48 Subgroup Analyses From the Phase 3 DIAMOND Trial
por: Huhn, Gregory D, et al.
Publicado: (2019)

Switch to Stribild versus continuation of NVP or RPV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-NNRTI subgroup analysis
por: Stellbrink, Hans-Juergen, et al.
Publicado: (2014)

1586. Phase 3/3b Experience with Long-Acting Cabotegravir and Rilpivirine: Efficacy and Safety Outcomes Through Week 96 by Race
por: Patel, Parul, et al.
Publicado: (2022)

833. Efficacy and Safety of Long-Acting Cabotegravir + Rilpivirine in Participants with HIV/HCV Co-infection: ATLAS-2M 48-Week Results
por: D’Amico, Ronald, et al.
Publicado: (2021)

T Cells in Chronic Lymphocytic Leukemia: A Two-Edged Sword
por: Vlachonikola, Elisavet, et al.
Publicado: (2021)

Atazanavir Plus Cobicistat: Week 48 and Week 144 Subgroup Analyses of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial(§)
por: Gallant, Joel, et al.
Publicado: (2017)

The "Sword Stretcher"
Publicado: (1887)

Scalpel and Sword
Publicado: (1937)

The sword of honour : trilogy /
por: Waugh, Evelyn, 1903-1966
Publicado: (1984)

12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens
por: Luetkemeyer, Anne F., et al.
Publicado: (2016)

Double-edged sword.
Publicado: (1994)

A storm of swords /
por: R. Martin, George R.

Beat their swords into ploughshares
por: van der Oost, John
Publicado: (2015)

Sword Wounds of the Head
por: Barry, C. C.
Publicado: (1901)

Death of Sword Swallower
Publicado: (1917)

Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV
por: Rolle, Charlotte-Paige, et al.
Publicado: (2021)

The Chrysanthemum an the sword : patterns of japanese culture
por: Benedict, Ruth, 1887-1948
Publicado: (1946)

Crossing swords : politics and religion in Mexico /
por: Camp, Roderic A.
Publicado: (1997)

Triple Threat: Triple Pathogen Endocarditis
por: Gonzalez, Jessica M, et al.
Publicado: (2023)

Contribution of Dietary Supplements to Nutritional Adequacy in Race/Ethnic Population Subgroups in the United States
por: Blumberg, Jeffrey B., et al.
Publicado: (2017)

Health outcomes in a national sample of American Indian and Alaska Native adults: Differences between multiple-race and single-race subgroups
por: Running Bear, Ursula, et al.
Publicado: (2020)

Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study
por: Pozniak, Anton, et al.
Publicado: (2016)

The horn and the sword : the history of the bull as symbol of power and fertility /
por: Conrad, Jack Randolph
Publicado: (1957)

SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral Regimen
por: Campo, R., et al.
Publicado: (2013)

Breathless at the Point of a Sword
por: Sethi, Pooja, et al.
Publicado: (2016)

Fatal Sword Wound of the Abdomen
por: Shaw, Townsend
Publicado: (1894)

The double-edged sword of evolution
por: Kruzel-Davila, Etty, et al.
Publicado: (2017)

A double-edged sword
por: Vandebotermet, Martijn, et al.
Publicado: (2020)

The sword and the shunt: Scimitar syndrome
por: Canan, Arzu, et al.
Publicado: (2021)

The Tongue is Mightier than the Sword
por: Madhu, S. V., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_iclac4q64ci679kioke0h7h3dv